Business Context and Reporting Period
Company: Daxor Corp (DXR)
Filing Type: Form 8-K (Current Report)
Date of Report: March 15, 2021
Event: Announcement of a new contract award with the United States Air Force.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain comprehensive financial statements (e.g., revenue, profit, cash flow, margins, debt, or liquidity) for a reporting period. The only financial figure disclosed is the value of the new contract.
- New Contract Value: $750,000
Material Changes
The material change reported is the execution of a contract with the United States Air Force. The contract is for a "Novel Fluorescent Tracer and Phase-Two" project involving a Point-of-Care Optical Blood Volume Analyzer. No prior period financial comparisons are provided in this document.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the contract award but does not include forward-looking guidance, earnings outlook, or specific risk factors within the text of the 8-K itself.
Unusual Items: None reported beyond the standard contract award announcement.
Investor Verification Checklist
- Verify the terms and duration of the $750,000 Phase-Two contract with the US Air Force via the attached press release (Exhibit 99.1).
- Confirm the revenue recognition timeline for this contract in future quarterly filings (10-Q/10-K).
- Review the company's latest 10-K or 10-Q for baseline financial health, as this 8-K contains no balance sheet or income statement data.